Effect of MDR modulators verapamil and promethazine on gene expression levels of MDR1 and MRP1 in doxorubicin-resistant MCF-7 cells

Donmez Y., Akhmetova L., Iseri O. D., Kars M. D., GÜNDÜZ U.

CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol.67, no.4, pp.823-828, 2011 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 67 Issue: 4
  • Publication Date: 2011
  • Doi Number: 10.1007/s00280-010-1385-y
  • Journal Name: CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.823-828
  • Keywords: MDR reversal, MCF-7, Promethazine, Verapamil, BREAST-CANCER CELLS, MULTIDRUG-RESISTANCE, P-GLYCOPROTEIN, MEMBRANE-FLUIDITY, DRUG-RESISTANCE, REVERSAL, PHENOTHIAZINES, TRANSPORTERS, MECHANISMS, STRATEGIES
  • Middle East Technical University Affiliated: Yes

Abstract

One of the major problems of cancer chemotherapy is the development of multidrug resistance (MDR) phenotype. Among the numerous mechanisms of MDR, a prominent one is the increased expression of membrane transporter proteins, the action of which leads to decreased intracellular drug concentration and cytotoxicity of drugs. Among them, P-gp and MRP1, encoded by MDR1 and MRP1 genes, respectively, have been associated with MDR phenotype. Chemical modulators can be used to reverse MDR. These chemicals can either modulate MDR due to their substrate analogy (such as calcium channel blocker verapamil) or interact with phospholipid membranes (such as antihistaminic drug promethazine). This study focuses on the effect of verapamil and promethazine on the expression levels of MDR1 and MRP1 genes and the drug transport activity in doxorubicin-resistant MCF-7 breast carcinoma cell line.